ICICI Securities Ltd | Retail Equity Research Revenues declined 16% YoY to | 777 crore (I-direct estimate: | 828 crore) mainly on account of the higher base of gAbilify in the US. Domestic branded formulation sales grew mere 2% YoY to | 294 crore (I-direct estimates: | 326 crore) mainly due to price reduction in Azithral (anti-Infective) and demonetisation EBITDA margins were at 18.7% (I-direct estimate: 19.4%) vs. 42% in Q3FY16 owing to the high base of gAbilify margins...